Harvard Bioscience (HBIO) Return on Capital Employed (2011 - 2026)
Harvard Bioscience (HBIO) reported Return on Capital Employed of 66.25% for Q1 2026, up 17091.0% year-over-year from N/an in Q1 2025, and up 416.05% quarter-over-quarter from 20.96% in Q4 2025.
Harvard Bioscience (HBIO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 16 years of Return on Capital Employed data on file, last reported at 66.25% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 66.25%, up 17091.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 66.25% (up 17091.0% YoY), and the FY2025 annual result was 14.7%, down 1152.0% from the prior year.
- Return on Capital Employed grew to 66.25% in Q1 2026 per HBIO's latest filing, from 20.96% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 66.25% in Q1 2026 and troughed at 196.36% in Q2 2025.
- A 5-year average of 27.21% and a median of 3.31% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 18951 bps in 2025, then jumped 17091 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 1.57% in 2022, then jumped by 69 bps to 0.48% in 2023, then tumbled by 591 bps to 3.31% in 2024, then slumped by 533 bps to 20.96% in 2025, then surged by 416 bps to 66.25% in 2026.
- Business Quant data shows HBIO's Return on Capital Employed at 66.25% in Q1 2026, 20.96% in Q4 2025, and 188.74% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 17.54% |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 5.02% |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | - |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 25.95% |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 18.63% |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 19.44% |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 4.68% |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 12.74% |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 13.02% |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | 66.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.25% |
| Dec 31, 2025 | -20.96% |
| Sep 30, 2025 | -188.74% |
| Jun 30, 2025 | -196.36% |
| Mar 31, 2025 | -104.66% |
| Dec 31, 2024 | -3.31% |
| Sep 30, 2024 | -7.80% |
| Jun 30, 2024 | -6.85% |
| Mar 31, 2024 | -4.17% |
| Dec 31, 2023 | -0.48% |
| Sep 30, 2023 | 5.26% |
| Jun 30, 2023 | 2.75% |
| Mar 31, 2023 | 5.34% |
| Dec 31, 2022 | -1.57% |
| Sep 30, 2022 | -3.68% |
| Jun 30, 2022 | -0.35% |
| Mar 31, 2022 | -3.31% |
| Dec 31, 2021 | 1.56% |
| Sep 30, 2021 | 1.05% |
| Jun 30, 2021 | 0.78% |